Abstract

The threat of a major human influenza pandemic, in particular from highly aggressive strains such as avian H5N1, has emphasized the need for therapeutic strategies to combat these pathogens. At present, two inhibitors of sialidase (also known as neuraminidase), a viral enzyme that has a key role in the life cycle of influenza viruses, would be the mainstay of pharmacological strategies in the event of such a pandemic. This article provides a historical perspective on the discovery and development of these drugs — zanamivir and oseltamivir — and highlights the value of structure-based drug design in this process.

Author affiliations

1. Mark von Itzstein is at the Institute for Glycomics, Gold Coast Campus, Griffith University, Queensland 4222, Australia.
   Email: m.vonitzstein@griffith.edu.au

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.